drugset
drugset / Trial / NCT01792687

Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate

NCT01792687 ↗

Phase 1 Completed 6 enrolled Aragon Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase Ib, open label study of ARN-509 administered in combination with abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer.

Timeline

Start
2013-02-05
Primary completion
2014-05-10
Completion
2024-02-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Apalutamide Small molecule 120 mg Oral
Subject Apalutamide Small molecule 180 mg Oral
Subject Apalutamide Small molecule 240 mg Oral
Background Abiraterone acetate Small molecule 1000 mg Oral
Background Prednisone Other / unclassified 5 mg Oral

Indications

prostate cancer